Congratulations to Henrik Watz, MD, PhD, and our site in Ahrensburg (formerly Velocity Grosshansdorf), Germany, which is currently the top enroller for a global COPD trial!
Dr. Watz has just published his 250th full paper, detailing results from the Phase 2 AIRLEAF trial. This study could pave the way for new treatment options in bronchiectasis, and Dr. Watz’s team also served as the central sputum lab in this trial. Article: Article: https://pubmed.ncbi.nlm.nih.gov/39255990/
Recently in Vienna, Dr. Watz was involved in 10 presentations at ERS Congress 2024. This included a presentation on a new first-in-class COPD medication: a modified macrolide from EpiEndo.
More to come from this prolific team soon!
